Substituted benzimidazoles

1. A compound of general formula (I):

in which:

A represents

wherein * indicates the point of attachment of said groups with the rest of the molecule;

Z represents a —C(═O)N(H)R 1 or —C(═S)N(H)R 1 group;

R 1 represents a hydrogen atom or a C 1 -C 6 -alkyl- or C 3 -C 6 -cycloalkyl-group;

wherein said C 1 -C 6 -alkyl- or C 3 -C 6 -cycloalkyl-group is optionally substituted, identically or differently, with 1, 2, 3 or 4 groups selected from: halogen, —OH, —CN, C 1 -C 6 -alkyl-, C 1 -C 6 -alkoxy-;

R 2 represents a hydrogen atom or a C 1 -C 6 -alkyl- or C 3 -C 6 -cycloalkyl-group;

wherein said C 1 -C 6 -alkyl- or C 3 -C 6 -cycloalkyl-group is optionally substituted, identically or differently, with 1, 2, 3 or 4 groups selected from: halogen, OH, —CN, C 1 -C 6 -alkyl-, C 1 -C 6 -alkoxy-;

R 3 represents a hydrogen atom or a halogen atom or a —CN, C 1 -C 6 -alkyl-, —(CH 2 ) m —C 2 -C 6 -alkenyl, —(CH 2 ) m —C 4 -C 8 -cycloalkenyl, —(CH 2 ) m —C 2 -C 6 -alkynyl, —(CH 2 ) m —C 3 -C 6 -cycloalkyl, —(CH 2 ) m -(3- to 7-membered heterocycloalkyl), —(CH 2 ) m -(4- to 8-membered heterocycloalkenyl), aryl-C 1 -C 6 -alkyl-, heteroaryl-C 1 -C 6 -alkyl-, halo-C 1 -C 6 -alkyl-, R 6a (R 6b )N—C 1 -C 6 -alkyl-, halo-C 1 -C 6 -alkoxy-C 1 -C 6 -alkyl-, C 3 -C 6 -cycloalkyl-, 3- to 7-membered heterocycloalkyl-, C 2 -C 6 -alkenyl-, C 4 -C 8 -cycloalkenyl-, C 2 -C 6 -alkynyl-, aryl-, —C 1 -C 6 -alkyl-aryl, —C 1 -C 6 -alkyl-heteroaryl, heteroaryl-, C 1 -C 6 -alkyl-X—, —X—(CH 2 ) m —C 2 -C 6 -alkenyl, —X—(CH 2 ) m —C 4 -C 8 -cycloalkenyl, —X—(CH 2 ) m —C 2 -C 6 -alkynyl, —X—(CH 2 ) m —C 3 -C 6 -cycloalkyl, —X—(CH 2 ) m -(3- to 7-membered heterocycloalkyl), —X—(CH 2 ) m -(4- to 8-membered heterocycloalkenyl), aryl-X—, heteroaryl-X—, —C(═O)R 6 , —C(═O)N(H)R 6a , —C(═O)N(R 6a )R 6b , —C(═O)O—R 6 , —N(R 6a )R 6b , —NO 2 , —N(H)C(═O)R 6 , —OR 6 , —SR 6 , —S(═O)R 6 , —S(═O) 2 R 6 , —S(═O)(═NR 6a )R 6b , —S(═O) 2 N(R 6b )R 6c , —S—(CH 2 ) n —N(R 6a )R 6b , or —S—(CH 2 ) n -(3- to 7-membered heterocycloalkyl) group;

said

C 1 -C 6 -alkyl-, —(CH 2 ) m —C 2 -C 6 -alkenyl, —(CH 2 ) m —C 2 -C 6 -alkynyl, —(CH 2 ) m —C 3 -C 6 -cycloalkyl, aryl-C 1 -C 6 -alkyl-, heteroaryl-C 1 -C 6 -alkyl-, C 3 -C 6 -cycloalkyl-, 3- to 7-membered heterocycloalkyl-, C 2 -C 6 -alkenyl-, C 4 -C 8 -cycloalkenyl-, C 2 -C 6 -alkynyl-, aryl-, C 1 -C 6 -alkyl-X—, —X—(CH 2 ) m —C 2 -C 6 -alkenyl, —X—(CH 2 ) m —C 4 -C 8 -cycloalkenyl, —X—(CH 2 ) m —C 2 -C 6 -alkynyl, —X—(CH 2 ) m —C 3 -C 6 -cycloalkyl, —X—(CH 2 ) m -(3- to 7-membered heterocycloalkyl), —X—(CH 2 ) m -(4- to 8-membered heterocycloalkenyl), aryl-X—, heteroaryl-X—, —C 1 -C 6 -alkyl-aryl, —C 1 -C 6 -alkyl-heteroaryl or heteroaryl-group being optionally substituted, identically or differently, with 1, 2, 3, 4 or 5 R 7 groups;

R 4a , R 4b , R 4c , R 4d

represent, independently from each other, a hydrogen or halogen atom, or a —CN, C 1 -C 6 -alkyl-, C 1 -C 6 -alkoxy-, halo-C 1 -C 6 -alkyl-, halo-C 1 -C 6 -alkoxy-, R 6a (R 6b )N—C 1 -C 6 -alkyl-, HO—C 1 -C 6 -alkyl-, NC—C 1 -C 6 -alkyl-, C 1 -C 6 -alkoxy-C 1 -C 6 -alkyl-, halo-C 1 -C 6 -alkoxy-C 1 -C 6 -alkyl-group;

R 5 represents a hydrogen atom or a C 1 -C 6 -alkyl-, —(CH 2 ) n —C 2 -C 6 -alkenyl, —(CH 2 ) n —C 2 -C 6 -alkynyl, —(CH 2 ) m —C 3 -C 6 -cycloalkyl, —(CH 2 ) m -(3- to 7-membered heterocycloalkyl), aryl-C 1 -C 6 -alkyl-, heteroaryl-C 1 -C 6 -alkyl-, halo-C 1 -C 6 -alkyl-, R 6a (R 6b )N—C 1 -C 6 -alkyl-, HO—C 1 -C 6 -alkyl-, —C 1 -C 6 -alkyl-CN, C 1 -C 6 -alkoxy-C 1 -C 6 -alkyl-, halo-C 1 -C 6 -alkoxy-C 1 -C 6 -alkyl-, C 3 -C 6 -cycloalkyl-, 3- to 7-membered heterocycloalkyl-, C 4 -C 8 -cycloalkenyl-, aryl- or heteroaryl-group;

said

C 1 -C 6 -alkyl-, —(CH 2 ) n —C 2 -C 6 -alkenyl, —(CH 2 ) n —C 2 -C 6 -alkynyl, —(CH 2 ) m —C 3 -C 6 -cycloalkyl, —(CH 2 ) m -(3- to 7-membered heterocycloalkyl), aryl-C 1 -C 6 -alkyl-, heteroaryl-C 1 -C 6 -alkyl-, halo-C 1 -C 6 -alkyl-, R 6a (R 6b )N—C 1 -C 6 -alkyl-, HO—C 1 -C 6 -alkyl-, —C 1 -C 6 -alkyl-CN, C 1 -C 6 -alkoxy-C 1 -C 6 -alkyl-, halo-C 1 -C 6 -alkoxy-C 1 -C 6 -alkyl-, C 3 -C 6 -cycloalkyl-, 3- to 7-membered heterocycloalkyl-, C 4 -C 8 -cycloalkenyl-, aryl- or heteroaryl- group being optionally substituted, identically or differently, with 1, 2, 3, 4 or 5 R 8 groups;

R 6 , R 6a , R 6b , R 6c

represent, independently from each other, a hydrogen atom or a C 1 -C 6 -alkyl-, HO—C 1 -C 6 -alkyl-, C 3 -C 6 -cycloalkyl-, C 2 -C 6 -alkenyl-, 3- to 7-membered heterocycloalkyl-, aryl-, heteroaryl-, aryl-C 1 -C 6 -alkyl- or heteroaryl-C 1 -C 6 -alkyl-group;

R 7 represents a hydrogen or halogen atom or a HO—, —CN, C 1 -C 6 -alkoxy-, halo-C 1 -C 6 -alkoxy-, C 1 -C 6 -alkyl-, halo-C 1 -C 6 -alkyl-, R 6a (R 6b )N—C 1 -C 6 -alkyl-, HO—C 1 -C 6 -alkyl-, C 1 -C 6 -alkoxy-C 1 -C 6 -alkyl-, halo-C 1 -C 6 -alkoxy-C 1 -C 6 -alkyl-, C 2 -C 6 -alkenyl-, C 2 -C 6 -alkynyl-, 3- to 7-membered heterocycloalkyl-, aryl-, heteroaryl-, —C(═O)R 6 , —C(═O)N(H)R 6a , —C(═O)N(R 6a )R 6b , —C(═O)O—R 6 , —N(R 6a )R 6b , —NO 2 , —N(H)C(═O)R 6 , —N(R 6c )C(═O)R 6 , —N(H)C(═O)N(R 6a )R 6b , —N(R 6c )C(═O)N(R 6a )R 6b , —N(H)C(═O)OR 6 , —N(R 6c )C(═O)OR 6 , —N(H)S(═O)R 6 , —N(R 6c )S(═O)R 6 , —N(H)S(═O) 2 R 6 , —N(R 6c )S(═O) 2 R 6 , —N═S(═O)(R 6a )R 6b , —OR 6 , —O(C═O)R 6 , —O(C═O)N(R 6a )R 6b , —O(C═O)OR 6 , —SR 6, —SF 5 , —S(═O)R 6 , —S(═O)N(H)R 6 , —S(═O)N(R 6a )R 6b , —S(═O) 2 R 6 , —S(═O) 2 N(H)R 6 , —S(═O) 2 N(R 6a )R 6b or —S(═O)(═NR 6c )R 6 group;

wherein said aryl- or heteroaryl-group is optionally substituted, identically or differently, with 1, 2 or 3 C 1 -C 6 -alkyl-groups;

or

when 2 R 7 groups are present ortho- to each other on an aryl ring, said 2 R 7 groups together form a bridge:

*O(CH 2 ) 2 O*, *O(CH 2 )O*, *NH(C(═O))NH*, wherein * represent the point of attachment to said aryl ring;

R 8 represents a hydrogen or halogen atom or a —CN, C 1 -C 6 -alkoxy-, C 1 -C 6 -alkyl-, halo-C 1 -C 6 -alkyl-, R 6a (R 6b )N—C 1 -C 6 -alkyl, HO—C 1 -C 6 -alkyl, C 1 -C 6 -alkoxy-C 1 -C 6 -alkyl-, halo-C 1 -C 6 -alkoxy-C 1 -C 6 -alkyl-, C 2 -C 6 -alkenyl-, C 2 -C 6 -alkynyl-, 3- to 7-membered heterocycloalkyl-, aryl-, heteroaryl-, —C(═O)R 6 , —C(═O)N(H)R 6a , —C(═O)N(R 6a )R 6b , —C(═O)O—R 6 , —N(R 6a )R 6b , —NO 2 , —N(H)C(═O)R 6 , —N(R 6c )C(═O)R 6 , —N(H)C(═O)N(R 6a )R 6b , —N(R 6c )C(═O)N(R 6a )R 6b , —N(H)C(═O)OR 6 , —N(R 6c )C(═O)OR 6 , —N(H)S(═O)R 6 , —N(R 6c )S(═O)R 6 , —N(H)S(═O) 2 R 6 , —N(R 6c )S(═O) 2 R 6 , —N═S(═O)(R 6a )R 6b , —OR 6 , —O(C═O)R 6 , —O(C═O)N(R 6a )R 6b , —O(C═O)OR 6 , —SR 6 , —S(═O)R 6 , —S(═O)N(H)R 6 , —S(═O)N(R 6a )R 6b , —S(═O) 2 R 6 , —S(═O) 2 N(H)R 6 , —S(═O) 2 N(R 6a )R 6b , —S(═O)(═NR 6c )R 6 or —S(═O) 2 -(3- to 7-membered heterocycloalkyl) group;

wherein said 3- to 7-membered heterocycloalkyl- or heteroaryl-group, is optionally substituted, identically or differently, with 1, 2, 3 or 4 C 1 -C 6 -alkyl-groups;

m is an integer of 0, 1, 2, 3, 4, 5, or 6;

n is an integer of 0, 1, 2, 3, 4, or 5; and

X is S, S(═O), S(═O) 2 , O, NR 6 , CR 6a R 6b , C(═CR 6a R 6b ), C(═O) or C(OH)(R 6a );

or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.

2. A compound according to claim 1 , wherein:

R 4a and R 4d represent hydrogen;

R 4b and R 4c are selected, independently from each other, from hydrogen, halogen, —CN, C 1 -C 6 -alkyl-, C 1 -C 6 -alkoxy-, halo-C 1 -C 6 -alkyl-, or halo-C 1 -C 6 -alkoxy-;

or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.

3. A compound according to claim 1 , wherein:

A represents

wherein * indicates the point of attachment of said group with the rest of the molecule;

Z represents a —C(═O)N(H)R 1 group;

R 1 represents a C 1 -C 6 -alkyl- or C 3 -C 6 -cycloalkyl-group;

wherein said C 1 -C 6 -alkyl- or C 3 -C 6 -cycloalkyl-group is optionally substituted, identically or differently, with 1, 2, 3 or 4 groups selected from: halogen, OH, —CN, C 1 -C 6 -alkyl-, C 1 -C 6 -alkoxy-;

or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.

4. A compound according to claim 1 , wherein:

R 3 represents a hydrogen atom or a halogen atom or an aryl-, heteroaryl-, aryl-X— or heteroaryl-X— group;

said aryl-, heteroaryl-, aryl-X— or heteroaryl-X— group being optionally substituted, identically or differently, with 1, 2 or 3 R 7 groups;

or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.

5. A compound according to claim 1 , wherein:

R 7 represents a halogen atom, or a HO—, —CN, C 1 -C 6 -alkoxy-, halo-C 1 -C 6 -alkoxy-, C 1 -C 6 -alkyl-, HO—C 1 -C 6 -alkyl-, 3- to 7-membered heterocycloalkyl-, heteroaryl-, —C(═O)N(H)R 6a , —OR 6 , —SR 6 , —SF 5 or —S(═O) 2 R 6 group;

or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.

6. A compound according to claim 1 , wherein:

R 5 represents a C 1 -C 6 -alkyl-, —(CH 2 ) m -(3- to 7-membered heterocycloalkyl) or halo-C 1 -C 6 -alkyl-group;

said C 1 -C 6 -alkyl-, —(CH 2 ) m -(3- to 7-membered heterocycloalkyl) or halo-C 1 -C 6 -alkyl-group is optionally substituted, identically or differently, with 1, 2, 3, 4 or 5 R 8 groups;

or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.

7. A compound according to claim 1 , wherein:

m is an integer of 0 or 1;

or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.

8. A compound according to claim 1 , wherein:

X is O, NR 6 , CR 6a R 6b , C(═CR 6a R 6b ), C(═O) or C(OH)(R 6a );

or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.

9. A compound according to claim 1 , which is selected from the group consisting of:

N-cyclopropyl-4-{4-[(2-methylpropyl)amino]-1H-benzimidazol-1-yl}benzamide,

N-cyclopropyl-2-methyl-4-{6-(pyridin-4-yl)-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimida zol-1-yl}benzamide,

N-cyclopropyl-4-{6-[(5-fluoro-2-methylphenyl)amino]-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

N-cyclopropyl-4-{6-(3-fluorophenoxy)-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

N-cyclopropyl-4-{6-[(2,3-difluorophenyl)amino]-4-[(3,3,3-trifluoropropyl)amino]-1H-benzi midazol-1-yl}-2-methylbenzamide,

4-{6-bromo-4-[(2-methylpropyl)amino]-1H-benzimidazol-1-yl}-N-cyclopropylbenzamide,

N-cyclopropyl-4-{6-(4-fluorophenyl)-4-[(2-methylpropyl)amino]-1H-benzimidazol-1-yl}benzamide,

N-cyclopropyl-4-{4-[(2-methylpropyl)amino]-6-phenyl-1H-benzimidazol-1-yl}benzamide,

N-cyclopropyl-4-{6-(3-fluorophenoxy)-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

4-{6-(3-fluorophenoxy)-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-N,2-dimethylbenzamide,

N-ethyl-4-{6-(3-fluorophenoxy)-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

4-{6-(3-fluorophenoxy)-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-2-methyl-N-(1-methylcyclopropyl)benzamide,

N-(1-cyanocyclopropyl)-4-{6-(3-fluorophenoxy)-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

N-cyclopropyl-4-{6-(2,3-difluorophenoxy)-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

N-cyclopropyl-4-{6-(3-fluoro-5-methylphenoxy)-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

N-cyclopropyl-4-{6-(5-fluoro-2-methylphenoxy)-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

N-cyclopropyl-4-{6-(3,4-difluorophenoxy)-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

4-{6-(4-chlorophenoxy)-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-N-cyclopropyl-2-methylbenzamide,

N-cyclopropyl-4-{6-[(5-fluoro-2-methylphenyl)amino]-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

N-cyclopropyl-4-{6-[2-(hydroxymethyl)phenyl]-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

N-cyclopropyl-4-{6-[2-(hydroxymethyl)phenyl]-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

4-{6-(4-chloro-3-fluorophenoxy)-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]-1H-benzimidazol-1-yl}-N-cyclopropyl-2-methylbenzamide,

4-{6-(4-chlorophenoxy)-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]-1H-benzimidazol-1-yl}-N-cyclopropyl-2-methylbenzamide,

N-cyclopropyl-4-{6-(2-fluoro-4-methoxyphenoxy)-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

N-cyclopropyl-4-{6-(2,3-difluorophenoxy)-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

N-cyclopropyl-4-{6-(3-fluoro-5-methylphenoxy)-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

N-cyclopropyl-4-{6-(3,4-difluorophenoxy)-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

4-{6-(4-chloro-3-fluorophenoxy)-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-N-cyclopropyl-2-methylbenzamide,

N-cyclopropyl-4-{6-(2-fluoro-4-methoxyphenoxy)-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

N-cyclopropyl-2-methyl-4-{6-(1-methyl-1H-pyrazol-5-yl)-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}benzamide,

N-ethyl-2-methyl-4-{6-(1-methyl-1H-pyrazol-5-yl)-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}benzamide,

N,2-dimethyl-4-{6-(1-methyl-1H-pyrazol-5-yl)-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}benzamide,

N-cyclopropyl-4-{6-(3-fluoro-4-methoxyphenoxy)-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

N-ethyl-4-{6-(3-fluoro-4-methoxyphenoxy)-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

4-{6-(3-fluoro-4-methoxyphenoxy)-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-N,2-dimethylbenzamide,

N-cyclopropyl-4-{6-(2,3-difluorophenoxy)-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}benzamide,

N-cyclopropyl-4-{6-phenoxy-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}benzamide,

N-cyclopropyl-4-{6-(3-fluoro-4-methoxyphenoxy)-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}benzamide,

4-{6-(2-methoxyphenoxy)-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-N,2-dimethylbenzamide,

N-ethyl-4-{6-(2-methoxyphenoxy)-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

N-cyclopropyl-4-{6-(2-methoxyphenoxy)-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

4-{6-(3-fluoro-4-methoxyphenoxy)-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]-1H-benzimidazol-1-yl}-N,2-dimethylbenzamide,

N-ethyl-4-{6-(3-fluoro-4-methoxyphenoxy)-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

N-cyclopropyl-4-{6-(3-fluoro-4-methoxyphenoxy)-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

4-{6-[4-(benzyloxy)phenoxy]-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-N-cyclopropyl-2-methylbenzamide,

4-{6-[4-(benzyloxy)phenoxy]-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-N-ethyl-2-methylbenzamide,

4-{6-[4-(benzyloxy)phenoxy]-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-N,2-dimethylbenzamide,

4-{6-(4-hydroxyphenoxy)-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-N,2-dimethylbenzamide,

N-ethyl-4-{6-(4-hydroxyphenoxy)-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

N-cyclopropyl-4-{6-(4-hydroxyphenoxy)-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

4,4′-{4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazole-1,6-diyl}bis(N-cyclopropyl-2-methylbenzamide),

4-{1-[4-(cyclopropylcarbamoyl)-3-methylphenyl]-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-6-yl}-N,2-dimethylbenzamide,

4-{1-[4-(cyclopropylcarbamoyl)-3-methylphenyl]-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-6-yl}-N-ethyl-2-methylbenzamide,

N-cyclopropyl-4-{6-(2-hydroxyphenoxy)-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

N-ethyl-4-{6-(2-hydroxyphenoxy)-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

4-{6-(2-hydroxyphenoxy)-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-N,2-dimethylbenzamide,

N-cyclopropyl-4-{6-(3-fluoro-2-methoxyphenoxy)-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

N-cyclopropyl-2-methyl-4-{6-[3-(trifluoromethoxy)phenoxy]-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}benzamide,

N-cyclopropyl-2-methyl-4-{6-[4-(morpholin-4-yl)phenoxy]-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}benzamide,

N-cyclopropyl-4-{6-[4-(difluoromethoxy)phenoxy]-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

N-cyclopropyl-4-{6-[3-(difluoromethoxy)phenoxy]-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

N-cyclopropyl-4-{6-[(2-methoxyphenyl)amino]-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

N-cyclopropyl-2-methyl-4-{6-[3-(methylsulfonyl)phenoxy]-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}benzamide,

N-cyclopropyl-4-{6-[(3-methoxy-2-methylphenyl)amino]-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

4-{6-(2,3-difluorophenoxy)-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-N-ethyl-2-methylbenzamide,

4-{6-(2,3-difluorophenoxy)-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-N,2-dimethylbenzamide,

4-{6-(3-methoxyphenoxy)-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-N,2-dimethylbenzamide,

N-ethyl-4-{6-(3-methoxyphenoxy)-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

N-cyclopropyl-4-{6-(3-methoxyphenoxy)-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

N-ethyl-4-{6-(3-fluoro-2-methoxyphenoxy)-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

4-{6-(3-fluoro-2-methoxyphenoxy)-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-N,2-dimethylbenzamide,

4-{6-(4-cyano-2-methoxyphenoxy)-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-N-cyclopropyl-2-methylbenzamide,

N-cyclopropyl-2-methyl-4-{6-[4-(methylsulfonyl)phenoxy]-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}benzamide,

N-cyclopropyl-2-methyl-4-{6-[4-(1,3-oxazol-2-yl)phenoxy]-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}benzamide,

N-cyclopropyl-4-{6-[4-fluoro-3-(trifluoromethyl)phenoxy]-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

4-{6-(3-cyanophenoxy)-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-N-cyclopropyl-2-methylbenzamide,

N-cyclopropyl-2-methyl-4-{6-[4-(1H-1,2,4-triazol-1-yl)phenoxy]-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}benzamide,

N-cyclopropyl-4-{6-[3-(cyclopropylcarbamoyl)phenoxy]-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

N-cyclopropyl-4-{6-[(2-hydroxyphenyl)amino]-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

N-cyclopropyl-4-{6-(3-fluoro-4-hydroxyphenoxy)-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

4-{6-(2,3-difluorophenoxy)-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]-1H-benzimidazol-1-yl}-N,2-dimethylbenzamide,

4-{6-(2,3-difluorophenoxy)-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]-1H-benzimidazol-1-yl}-N-ethyl-2-methylbenzamide,

4-{6-(2-fluoro-4-methoxyphenoxy)-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]-1H-benzimidazol-1-yl}-N,2-dimethylbenzamide,

N-ethyl-4-{6-(2-fluoro-4-methoxyphenoxy)-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

4-{6-(2-fluoro-4-methoxyphenoxy)-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-N,2-dimethylbenzamide,

N-ethyl-4-{6-(2-fluoro-4-methoxyphenoxy)-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

N-cyclopropyl-4-{6-(2-fluoro-4-hydroxyphenoxy)-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

N-cyclopropyl-4-{6-(3-fluoro-2-hydroxyphenoxy)-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

4-{6-(3-fluoro-2-hydroxyphenoxy)-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-N,2-dimethylbenzamide,

N-ethyl-4-{6-(3-fluoro-2-hydroxyphenoxy)-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

4-{6-(3-hydroxyphenoxy)-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-N,2-dimethylbenzamide,

N-ethyl-4-{6-(3-hydroxyphenoxy)-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

N-cyclopropyl-2-methyl-4-{6-[3-(pentafluoro-lambda6-sulfanyl)phenoxy]-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}benzamide,

4-{6-(2-fluoro-4-hydroxyphenoxy)-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-N,2-dimethylbenzamide,

N-ethyl-4-{6-(2-fluoro-4-hydroxyphenoxy)-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

4-{6-(3-fluoro-4-hydroxyphenoxy)-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-N,2-dimethylbenzamide,

N-ethyl-4-{6-(3-fluoro-4-hydroxyphenoxy)-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

N-cyclopropyl-4-{6-(3-fluoro-4-methoxybenzoyl)-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

N-cyclopropyl-4-{6-[(3-fluoro-4-methoxyphenyl)(hydroxy)methyl]-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

N-cyclopropyl-4-{6-[(1RS)-1-(3-fluoro-4-methoxyphenyl)-1-hydroxyethyl]-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

N-cyclopropyl-4-{6-[(1RS)-1-(3-fluoro-4-methoxyphenyl)-1-hydroxyethyl]-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-2-(hydroxymethyl)benzamide,

N-cyclopropyl-4-{6-[1-(3-fluoro-4-methoxyphenyl)vinyl]-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

N-cyclopropyl-4-{6-[(1RS)-1-(3-fluoro-4-methoxyphenyl)ethyl]-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

N-cyclopropyl-4-{6-(3-fluoro-4-methoxybenzyl)-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

N-cyclopropyl-4-{6-(5-fluoro-2-methylphenoxy)-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

N-cyclopropyl-4-{6-(3-fluoro-4-hydroxybenzoyl)-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

N-cyclopropyl-4-{6-[3-(difluoromethyl)phenoxy]-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

N-cyclopropyl-4-{6-(2-methoxybenzoyl)-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

N-cyclopropyl-4-{6-(3-hydroxyphenoxy)-4-[(3,3,3-trifluoropropyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

4-{6-(3-fluoro-4-hydroxyphenoxy)-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]-1H-benzimidazol-1-yl}-N,2-dimethylbenzamide,

N-ethyl-4-{6-(3-fluoro-4-hydroxyphenoxy)-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

N-ethyl-4-{6-[4-methoxy-3-(methylsulfanyl)phenoxy]-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

N-cyclopropyl-4-{6-(3-fluoro-4-hydroxyphenoxy)-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

N-cyclopropyl-4-{6-[4-methoxy-3-(methylsulfanyl)phenoxy]-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

4-{6-(2-fluoro-4-hydroxyphenoxy)-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]-1H-benzimidazol-1-yl}-N,2-dimethylbenzamide,

4-{6-[4-methoxy-2-(methylsulfanyl)phenoxy]-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]-1H-benzimidazol-1-yl}-N,2-dimethylbenzamide,

N-cyclopropyl-4-{6-(2-fluoro-4-hydroxyphenoxy)-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

N-cyclopropyl-4-{6-[4-methoxy-2-(methylsulfanyl)phenoxy]-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

N-ethyl-4-{6-(2-fluoro-4-hydroxyphenoxy)-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

N-ethyl-4-{6-[4-methoxy-2-(methylsulfanyl)phenoxy]-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]-1H-benzimidazol-1-yl}-2-methylbenzamide,

or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.

10. A method of preparing a compound according to claim 1 , said method comprising the step:

allowing an intermediate compound of general formula (II):

in which

R 5 and A are as defined in claim 1 ;

R 3 ′ is a halogen atom;

to react with a compound of general formula (IIa):

R 3 —Y  (IIa)

in which

R 3 is as defined in claim 1 ;

Y is a substituent which is displaced in a coupling reaction;

thereby giving a compound of general formula (I):

in which

R 3 , R 5 and A are as defined in claim 1 .

11. A method of preparing a compound according to claim 1 , said method comprising the step:

allowing an intermediate compound of general formula (IV):

in which

R 3 and R 5 are as defined in claim 1 ;

to react with a compound of general formula (IVa):

A-Y  (IVa)

in which

A is as defined in claim 1 ;

Y is a substituent which is displaced in a coupling reaction;

thereby giving a compound of general formula (I):

in which

R 3 , R 5 and A are as defined in claim 1 .

12. A pharmaceutical composition comprising a compound according to claim 1 , or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, or a mixture of same, and a pharmaceutically acceptable diluent or carrier.

13. A pharmaceutical composition comprising:

one or more compounds according to claim 1 , or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof, or a mixture of same; and

one or more agents selected from: a taxane, Docetaxel, Paclitaxel, Taxol; an epothilone, Ixabepilone, Patupilone, Sagopilone; Mitoxantrone; Predinisolone; Dexamethasone; Estramustin; Vinblastin; Vincristin; Doxorubicin; Adriamycin; Idarubicin; Daunorubicin; Bleomycin; Etoposide; Cyclophosphamide; Ifosfamide; Procarbazine; Melphalan; 5-Fluorouracil; Capecitabine; Fludarabine; Cytarabine; Ara-C; 2-Chloro-2′-deoxyadenosine; Thioguanine; an anti-androgen, Flutamide, Cyproterone acetate, Bicalutamide; Bortezomib; a platinum derivative, Cisplatin, Carboplatin; Chlorambucil; Methotrexate; and Rituximab.

14. A method for inhibiting monopolar spindle 1 kinase activity in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound according to claim 1 .

15. A compound of general formula (II):

in which R 5 and A are as defined in claim 1 and R 3 ′ is a halogen atom.

16. The method of claim 14 , wherein the uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune response, or inappropriate cellular inflammatory response is mediated by the mitogen-activated protein kinase (MEK-ERK) pathway.

17. The method of claim 14 , wherein the disease of uncontrolled cell growth, proliferation and/or survival, inappropriate cellular immune response, or inappropriate cellular inflammatory response is a haematological tumour, a solid tumour and/or metastases thereof.

18. The method of claim 17 , wherein the haematological tumour, solid tumour and/or metastases thereof, is selected from leukaemias and myelodysplastic syndrome, malignant lymphomas, head and neck tumours, brain tumours and brain metastases, tumours of the thorax, non-small cell and small cell lung tumours, gastrointestinal tumours, endocrine tumours, mammary and other gynaecological tumours, urological tumours, renal, bladder and prostate tumours, skin tumours, and sarcomas, and/or metastases thereof.